CCCanan Can

Canan Can

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Canan Can has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • One Tracer, Whole Syndrome

    by Esra Arslan, Halil Kömek, Canan Can, Elife Akgün, Okan Türk, Uğur Yücetaş, Tevfik Fikret Cermik, Ali Rıza Kural

    Von Hippel-Lindau (VHL) is hereditary syndrome characterized with benign and malignant neoplasms resulting from dysregulation of hypoxia-sensitive pathway. Fifty-year-old man with VHL underwent multimodal imaging for remaining CNS disease. ⁶⁸Ga-DOTATATE PET/CT showed single cerebellar lesion, while ¹⁸F-FDG PET/CT remained negative despite active disease; [⁶⁸Ga]Ga-DPI-4452 CAIX-targeted PET/CT revealed multisystem tumor burden; cerebellar and spinal hemangioblastomas, recurrent and contralateral ccRCC lesions and epididymal involvement. This case demonstrates the ability of CAIX-targeted imaging to visualize the pervasive hypoxia-induced phenotype underlying VHL-associated neoplasms, detect biologically active but metabolically latent disease, and may represent promising molecular imaging approach for phenotype-focused evaluation of inherited tumor syndromes.

  • Head-to-Head Comparison of [ 68 Ga]Ga-DOTATATE PET/CT and [ 68 Ga]Ga-NODAGA-LM3 PET/CT

    by Canan Can, Halil Kömek, Yunus Güzel, Nadiye Akdeniz, Hüseyin Karaoğlan, İhSan Kaplan, Fatih Güzel, Ömer Yeprem, Erkan Akyıldız, Ferat Kepenek

    This study compared the physiologic distribution of [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3 PET/CT, assessed SUV and tumor-to-background ratio (TBR) measurements in primary and metastatic lesions, and evaluated lesion detection performance. Methods: Forty-one adult patients with well-differentiated (G1–G3) gastroenteropancreatic or lung neuroendocrine neoplasms, pheochromocytoma, medullary thyroid carcinoma, and well-differentiated thyroid carcinoma were included in this study. All patients underwent PET/CT imaging with both [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3 within a 3-d interval. SUVmax and SUVmean were calculated for physiologic uptake regions, and SUVmax and TBR were determined for lesions. Paired data were analyzed using the paired-samples t test or Wilcoxon signed-rank test, with a P of less than 0.05 considered statistically significant. Results: The median patient age was 62 y (range, 27–90 y), and 63.4% were women. Analysis of uptake in normal organs revealed that [68Ga]Ga-DOTATATE PET/CT demonstrated significantly higher physiologic activity in the liver, spleen, pancreas, and jejunum, whereas [68Ga]Ga-NODAGA-LM3 showed significantly higher uptake in the parotid glands, mediastinal blood pool, lungs, breasts, kidneys, and uterus. Lesion-based analysis found that [68Ga]Ga-NODAGA-LM3 detected significantly more liver metastases than did [68Ga]Ga-DOTATATE (P < 0.05), with no significant differences observed in other regions. The TBR of liver metastases was significantly higher with [68Ga]Ga-NODAGA-LM3 (P = 0.006), although the SUVmax did not significantly differ between radiotracers. Conclusion: [68Ga]Ga-NODAGA-LM3 demonstrates a higher TBR and superior detection of liver metastases compared with [68Ga]Ga-DOTATATE. Although no significant differences were found in other regions, the 2 radiotracers exhibit distinct physiologic distribution patterns. Visual Abstract


  • Association of Fat and Muscle Mass With Overall Survival in Patients With Metastatic Prostate Cancer Treated With Enzalutamide, Abiraterone, and Docetaxel

    by İhSan Solmaz, Halil Kömek, Fethullah Kayan, Canan Can, İhSan Kaplan, Rıdvan Kiliç, Yunus Güzel, Mehmet Serdar Yildirim, Ömer Faruk Alakuş, Bilgin Bahadır Başgöz, et al.

  • 68Ga-CXCR4-targeted PET/CT Outperforms 18F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma

    by Özlem Beyler, Halil Kömek, Yunus Güzel, Cengiz Demir, Canan Can

    68 Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18 F-FDG PET/CT. Compared with 18 F-FDG PET/CT, 68 Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68 Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.

  • Open Access

    Prognostic importance of PET score obtained from IMPeTUS criteria in multiple myeloma

    by Özlem Beyler, İhSan Kaplan, Cengiz Demir, Canan Can, Halil Kömek

    Aim Multiple myeloma (MM) is a clonal plasma cell malignancy that infiltrates the bone marrow, bone, and sometimes extramedullary sites. Reliable staging and prognostic factors are essential for patient management. Imaging modalities, especially [18F]FDG PET/CT, are essential for the assessment of disease extent. This study evaluates a scoring system based on the IMPeTUs criteria for predicting progression-free survival (PFS) in MM. Materials and Methods This study included 35 newly diagnosed, treatment-naive MM patients (13 females, 22 males). Baseline [18F]FDG PET/CT scans were obtained within one month of diagnosis. Data on MM type, ISS stage, chemotherapy regimens and outcomes were collected. PET/CT scans were evaluated using the IMPeTUs criteria, focusing on the Deauville 5-point scoring system for bone marrow and lesions. Results The mean age of the cohort was 65 years. Ig G kappa was the most common MM type (37.1%). Diffuse bone marrow uptake and focal lesions were observed in 37.2% and 57.2% of patients, respectively, DS ≥ 4. The PET score cut-off of 6.5 predicted PFS with 61.5% sensitivity and 72.7% specificity (AUC 0.715). Median PFS was significantly different between patients with PET score < 6.5 and ≥ 6.5 (35 ± 4.1 months vs. 23.6 ± 4.03 months, p = 0.027). Conclusions The PET score cut-off value of 6.5 serves as a potential prognostic tool for MM, aiding in patient stratification and treatment decisions.

  • Open Access

    Predictive value of the FIB-4 index, APRI, ALBI score, and GPR for overall survival in treatment-naïve metastatic colorectal cancer patients

    by Mehmet Serdar Yıldırım, Yunus Güzel, Canan Can, İhSan Kaplan, Veysi Şenses, İhSan Solmaz, Bilgin Bahadır Başgöz, Ömer Faruk Alakuş, Serdar İlEri, Halil Kömek

    The prevalence of metastatic colorectal cancer (mCRC) is increasing and is linked to poor overall survival (OS). Previous studies have aimed to determine the predictive value of scores and laboratory tests for OS in mCRC patients, but their findings have been inconclusive. In this research, we focused on determining the prognostic significance of the fibrosis-4 (FIB-4) index, the aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), the albumin–bilirubin (ALBI) score, and the gamma-glutamyl transpeptidase to PLT ratio (GPR) with respect to OS in treatment-naïve mCRC patients. This retrospective study included treatment-naïve mCRC patients. The FIB-4 index, ALBI score, APRI, and GPR were calculated for each participant, and their mortality dates were recorded. The clinical importance of these scores for survival outcomes was evaluated via the Cox regression model, Kaplan–Meier method, and log-rank test. The study enrolled 123 untreated mCRC patients. Univariate Cox regression analysis demonstrated that sex and AST/PLT and ALT/PLT counts were not associated with OS (p > 0.05 for all). However, a higher FIB-4 index (p = 0.025), ALBI score (p < 0.001), GPR (p < 0.001), and AST/ALT ratio (p < 0.001) were all associated with poor OS. Additionally, multivariate Cox regression analysis indicated that age (95% CI: 1.009–1.053, p = 0.006), ALBI score (95% CI: 1.234–2.983, p = 0.004), GPR (95% CI: 1.442–2.701, p < 0.001), and AST/ALT (95% CI: 1.193–2.911, p = 0.006) were independent prognostic factors for OS. The affordable and easily accessible ALBI score, GPR, and AST/ ALT have prognostic value in untreated patients with mCRC.


  • Open Access

    The effect of proton pump inhibitor use on the biodistribution of FDG in patients undergoing 18F FDG PET/CT imaging

    by İhSan Kaplan, Yunus Güzel, Canan Can, Cihan Gündoğan, Mehmet Serdar Yildirim, Ferat Kepenek, Bekir Taşdemi̇r, Halil Kömek

    Aim: In this study, we aimed to investigate the effects of proton pump inhibitors (PPIs) administered shortly before intravenous (iv) F-18 fluorodeoxyglucose (FDG) injection on the physiological FDG uptake in the gastrointestinal tract (GIS) of patients undergoing F-18 FDG positron emission tomography/computed tomography (PET/CT) for oncological purposes. Material and Method: We retrospectively evaluated 350 patients who underwent 18F-FDG PET/CT in our clinic between November 2020 and June 2021. Among these, 178 patients were given iv PPIs before the scan and the remaining 172 patients with similar characteristics were not. FDG uptake in the gastrointestinal tract was analyzed visually and quantitatively. Results: The mean age of the patients was 51.7±15 years. There was no significant difference between the two groups in terms of age and gender. Quantitative evaluation revealed that the FDG uptakes in the stomach, duodenum, ileum, and transverse colon and their ratio to hepatic uptake were significantly lower in the group receiving iv PPIs (p

  • Open Access

    FAPI-04 Uptake in Healthy Tissues of Cancer Patients in 68Ga-FAPI-04 PET/CT Imaging

    by Cihan Gündoğan, Yunus Güzel, Canan Can, Ihsan Kaplan, Halil Kömek

    Objective. The aim of this study is to investigate the uptake of 68Ga-FAPI-04 in normal tissues and calculate standardized uptake values (SUVs) for various organs in the body. Methods. A total of 49 patients who underwent 68Ga-FAPI-04 PET/CT were included in our study. The following organs were identified on CT images: brain, parotid, and submandibular glands, palatine tonsils, thyroid, lymph nodes (if present), breasts, lungs, thymus, left ventricle walls, mediastinal blood pool, vertebral bone marrow, liver, spleen, pancreas, stomach, small and large intestines, adrenal glands, kidneys, uterus, testes, and prostate. Median, minimum, and maximum values (max) and average (avg) values of standard uptake value (SUV) of tissues and organs were calculated. Results. The accumulation of 68Ga-FAPI in normal organs showed variations. The cerebral/cerebellar cortex exhibited no 68Ga-FAPI uptake, while the scalp showed low uptake. Low uptake was also observed in the lung parenchyma, esophagus, left ventricle walls, nipple, and glandular breast tissue. In the abdominopelvic area, the pancreas exhibited low uptake, which was higher in the tail region. Low uptake was observed in the renal cortex. Intense 68Ga-FAPI uptake was observed throughout the uterus, which was higher in the corpus. There was no uptake of 68Ga-FAPI in the bone cortex and medulla. Conclusion. We determined the physiological uptake and SUVmax of FAPI-04 in different tissues and organs and created a guide for researchers.


  • Open Access

    A Case with 68Ga-FAPI Positive and 18F-FDG Negative Breast Cancer

    by Halil Kömek, Cihan Gündoğan, Hülya Etem, Canan Can

    A female patient diagnosed of infiltrative breast carcinoma using tru-cut biopsy underwent 18flourine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for staging. The tumor was located in the superior external quadrant of the right breast, and did not exhibit pathological uptake in 18F-FDG PET/CT. Later, gallium-68 (68Ga) fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT imaging was performed and the primary tumor showed intense radiotracer accumulation. This presumes that 68Ga-FAPI PET/CT imaging is superior to 18F-FDG imaging in detecting the primary tumor in breast cancer, thereby suggesting the replacement of FAPI by 18F-FDG in breast-cancer staging in the future.


  • Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

    by Ozgen Ahmet Yildirim, Kerem Poyraz, Erkan Erdur, Canan Can, Cihan Gundogan, Yunus Guzel, Hülya Etem, Halil Kömek

    To evaluate ICIs related dry eye and dry mouth in nivolumab therapy, 24 patients receiving nivolumab (group 1), 30 patients in remission without treatment for 6 months (group 2), 30 healthy participants (group 3) were cross-sectionally examined. Schirmer’s 1, 2, TSH blood tests, serological analysis, salivary flow scintigraphy and minor-salivary gland biopsy were performed. Schirmer’s tests were performed with anesthetic (1) and without anesthetic (2). Schirmer’s scores were lower in group 1 with more frequent reduced tear production (p < 0.001). TSH levels negatively correlated with Schirmer’s scores. Functional insufficiency was detected by salivary flow scintigraphy in 7 out of 10 patients with Schirmer's test positivity. In Schirmer’s positive patients, lymphocytic sialadenitis was confirmed in 4 patients (focus score >1) and CD4 T lymphocyte precipitation was observed in 6 patients. Nivolumab therapy may be associated with ICIs related immune sicca.